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Desferrioxamine regulates tumor necrosis factor release in mesangial
cells. Cultured rat mesangial cells have been demonstrated to express
tumor necrosis factor a (TNFa) mRNA and to release TNF activity into
the medium upon stimulation by bacterial lipopolysaccharide (LPS).
The present study was undertaken to determine whether TNF was only
secreted by mesangial cells or was also present as a cell-associated
molecule. LPS-activated mesangial cells which had been fixed in
paraformaldehyde lysed the TNF-sensitive L-929 fibroblasts, as as-
sessed by 51Cr release. This cytotoxic activity was inhibited by anti-
TNFa antiserum. Cell-associated TNF expression was demonstrable
after less than one hour of exposure to LPS, peaked at two hours and
decreased progressively thereafter, while TN F activity increased in the
medium. Mesangial cell-associated TNF was localized at the cell
surface, as shown by immunohistochemical demonstration and by the
ability of plasma membranes purified from LPS-activated mesangial
cells to lyse L-929 fibroblasts. Flow cytometry experiments revealed
that two-thirds of LPS-activated mesangial cells were stained by
anti-TNFa antiserum. The major part of these cell-associated TNF
molecules persisted after low pH treatment, indicating that they were
integral membrane proteins. As assessed by immunoprecipitation anal-
ysis, these proteins were 26 kDa molecules, whereas the released forms
of TNF were 17 kDa molecules, Pretreatment of mesangial cells with
desferrioxamine (DFX), an iron chelator preventing the synthesis of
hydroxyl radicals (0H), delayed the release of TNF from the mem-
branes into the medium, and enhanced its cell surface expression. It
also subsequently accelerated its decay in the medium. This indicates
that 0H could be involved in the mechanism of TNF detaching from
the membranes and in that of TNF preservation. Taken together, these
data suggest that during endotoxic shock DFX could represent a new
way to prevent TNF release from mesangial cells into the blood stream
while maintaining the local response to TNF.
Tumor necrosis factor (TNF) is a potent proinflammatory
polypeptide, mainly produced by monocytes/macrophages
upon activation with bacterial lipopolysaccharide (LPS) [1],
immune complexes [21, and various cytokines [reviewed in 3].
This mediator is not only secreted as a soluble protein but is
also expressed as a cell surface-associated molecule, that has
been identified as a 17-kDa protein bound to its receptor [4],
and/or a 26-kDa transmembrane protein [5, 61. Recent studies
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have demonstrated that TNF can contribute to the pathology of
three different models of renal injury: i) In acute nephrotoxic
nephritis, glomerular basement membrane-containing immune
complexes stimulate TNF production by monocytes/macro-
phages [7] potentially invading the glomerulus [8]; ii) In lupus
nephritis, TNF mRNA is expressed in the renal cortex and in
the macrophages cultured from glomeruli [91; iii) TNF mRNA
expression is also increased in the kidney, to a greater extent
than in any other tissue, in an experimental model of septic
shock [10], In the latter instance, the cellular source of TNF is
likely to involve resident kidney cells besides blood-borne cells.
Consistent with this hypothesis, recent reports demonstrated
that LPS induces TNF mRNA expression by clonal lines of
transformed tubular cells [11], and by glomerular mesangial
cells in primary culture [12]. During LPS activation, the secre-
tion of TNF by mesangial cells has been well characterized [12],
whereas the cell surface expression of TNF has never been
demonstrated in these cells.
There is in vitro evidence of bidirectional interaction between
TNF and reactive oxygen species (ROS), which both are
generated by monocytes/macrophages and mesangial cells [13].
TNF is capable of stimulating ROS production by these cells
[14, 15], and ROS, in turn, may enhance the release of TNF by
macrophages [16]. However, how plasma-membrane associated
TNF expression is affected by ROS has never been determined.
To elucidate these questions, we first examined whether a
membrane-associated form of TNF was expressed by LPS-
activated mesangial cells, in a second set of experiments, we
studied the cell surface expression and the release of TNF by
LPS-activated mesangial cells upon addition of desferrioxamine
(DFX), which inhibits the hydroxyl radical (OH') formation,
that is, the ultimate mechanism of ROS toxicity. We present
evidence that: i) TNF is secreted by LPS-activated mesangial
cells but is also present as a cell surface-associated molecule; ii)
DFX reduces the concentration of TNF in the medium through
a decrease of its release and an acceleration of its inactivation,
without reducing its cell surface expression. This differential
regulation might ensure a strictly localized action of TNF in the
glomerulus under various pathologic conditions, without trig-
gering any noxious consequences at more distant sites.
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Methods
Mesangial cell culture
Mesangial cells were cultured from isolated rat glomeruli
according to a method previously described [13]. Briefly, gb-
meruli were prepared from the renal cortices of Sprague-
Dawley rats weighing 100 to 150 g by sieving techniques and
differential centrifugations. After treatment with 300 U/ml of
collagenase (300 U/mg; Sigma Chemical Co., St Louis, Mis-
souri, USA) for 30 minutes at 37°C, isolated glomeruli were
resuspended in RPMI 1640 medium (Flow Laboratories, Irvine,
UK) buffered with 20 mri N-2-hydroxyethyl-piperazine-N'-2-
ethanesulfonic acid (HEPES) to pH 7.4, and supplemented with
10% fetal calf serum (FCS), 100 U/mI penicillin, 100 g/ml
streptomycin, and 2 mM glutamine. Then they were plated onto
plastic Petri dishes (Nunc, Roskilde, Denmark) and cultured at
37°C in 5% CO2 in humidified air. Under such conditions,
mesangial cells reached confluency by day 21. Near confluent
cells in primary culture were used in these studies. Macrophage
contamination was excluded as previously described [13].
Cell incubation procedure
The Petri dishes were rinsed with serum-free culture medium,
and the medium was replaced with 3 ml of fresh RPM!- 1640
medium containing 1% FCS, 1 g/ml bacterial LPS (from E.
Coil 026B6; Sigma Chemical Co.), together with the drug to be
tested: dimethylthiourea (DMTU, Merck, Schuchardt, Germa-
ny), or DFX (Desferal, Ciba, Rueil-Malmaison, France). After
one to 18 hours of incubation, the cell-free supernates were
collected, and mesangial cells were fixed or lysed to obtain the
membrane-containing fraction, before both components were
assayed for TNF activity. In some experiments, 51Cr-release
from 51Cr-labeled cells and LDH release were studied after 18 h
incubation to determine the cytotoxicity of DFX against mesan-
gial cells.
Fixation of mesangial cells
Unactivated or LPS-activated mesangial cells were treated
with trypsin/EDTA (0.05% trypsin and 0.02% EDTA, Flow
Laboratories) and detached by gently pipetting. After addition
of 40% FCS, the resulting cell suspension was centrifuged at
500 g for 10 minutes, and washed in Earle's balanced salt
solution devoid of calcium and magnesium but supplemented
with 26 m sodium bicarbonate (EBSS, Flow Laboratories).
The cells were then fixed with 2% paraformaldehyde for 20
minutes at room temperature, washed three times with EBSS,
and incubated with 100 mrvi glycine for 30 minutes at room
temperature for neutralizing the remaining paraformaldehyde.
After two washes, the cells were centrifuged and resuspended
at 2 X 106 cells/ml in culture medium containing 10% FCS. To
determine whether the cell-surface associated TNF activity was
due to molecules attached to their receptors or to integral
proteins, supplementary experiments were performed using
acid buffer treatment [6]. Mesangial cells which had been
activated with LPS were washed, and treated at 4°C for 10
minutes with 0.05 M glycine-HC1 buffer, pH 3.0, containing 0.15
M NaCI, or, as control, with phosphate-buffered saline, pH 7.4
(PBS). Thereafter, the cells were washed and fixed as indicated
above.
Preparation of mesangial cell plasma membranes
Plasma membranes of control and LPS-activated mesangial
cells were prepared at 4°C by a method described previously
[17, 18] with minor modifications. Mesangial cells were washed
twice with ice-cold PBS containing 1 mi dithiotreitol (DTT),
0.005 mM phenylmethylsulfonyl fluoride (PMSF), and 0.02% Na
N3 (homogenization buffer). The cells were then scraped away
from the dishes with a rubber policeman and centrifuged at 400
g for 10 minutes. The pellet was resuspended in the homogeni-
zation buffer, and the cells were disrupted using a glass homog-
enizer and a glass pestle. The homogenate was centrifuged (200
g) for 10 minutes before the supernatant was separated and
centrifuged (15,000 g) for 20 minutes. The plasma membrane
fraction was then isolated by centrifugation at 100,000 g for 30
minutes in a 35% sucrose gradient. The protein concentration of
the membranes was measured by the method of Lowry et a!
[191.
Tumor necrosis factor assay
The L-929 target cells were radiolabeled with 51Cr (51Cr-
sodium chromate, 5 Ci/ml, The Radiochemical Center, Amer-
sham, UK) by incubation at 37°C for 18 to 24 hours in 96-well
microplates (3 x iO cells per well), each well containing 100 .d
Minimum Essential Medium Eagle medium (MEM, Boehringer,
Mannheim, Germany) supplemented with 1% glutamine, 1%
non-essential amino acids, and 10% FCS. Thereafter, the cells
were washed twice to remove unbound 51Cr, and cultured with
fresh medium supplemented with 1 pg/m1 actinomycin D (Sigma
Chemical Co.) in the presence of serial dilutions of mesangial
cell-free supernatants, fixed mesangial cells, mesangial cell
plasma membranes, or mouse recombinant TNFa (4 x l0
U/mg; Genzyme, Boston, Massachusetts, USA). In neutraliz-
ing tests, the fixed mesangial cells were preincubated with
normal rabbit serum, or anti-mouse TNFa (106 neutralizing
units per ml; Genzyme) at a titer of 1:100 for 60 minutes at 37°C
before they were added to the target cell monolayers. After
incubation at 38°C for 24 to 48 hours in a humidified atmosphere
of 5% CO2 in air, the radioactivity was determined in both the
cell-free supernatants and the adherent cells which were lysed
with 100 d of 1 M NaOH. The cytotoxicity percentage was
calculated from the following formula: % specific cytotoxicity
= (R-S) x l00/(T-S) with R = cpm released in the presence of
agonist, S = cpm spontaneously released and T total cpm.
Immunolocalization of tumor necrosis factor by Immuno-
Gold Silver Staining (IGSS) technique
Mesangial cells were grown on rectangular glass coverslips
under the conditions indicated above. Unactivated or LPS-
activated cells were washed and fixed for 10 mm at room
temperature in a solution of 2% glutaraldehyde in PBS. After
washing in PBS, the slides were incubated at room temperature
successively with: 1) anti-mouse TNFa antiserum at a titer of
1:100 for 60 minutes, 2) biotinylated goat anti-rabbit IgG (Vec-
tor Laboratories, Burlingame, California, USA) for 30 minutes,
and 3) gold-labeled streptavidin (5 nm gold, Sigma Chemical,
Co) for 60 minutes [201. The slides were finally washed in
distilled water before amplification with silver enhancement
reagent (Janssen, Olen, Belgium) and counterstained by the
Giemsa method. Photographs were taken with combined bright-
824 Affres et al. Desferrioxamine and TNF
>-
0
00
>0
Fig. 1. Cell surface expression and release of TNF activity by mesan-
gial cells at various times following addition of I gIml LPS. Two 1d
supernatants (0) and 10,000 fixed cells (•) were tested for TNF activity
using the cytotoxicity assay on L-929 cells. Means and SEM of values
obtained in 3 experiments are given.
Number of cells, x 102/wel/
Fig. 2. Correlation of fixed mesangial cell density with the production
of cytotoxic activity, Mesangial cells were preincubated for two hours
with 1 g/ml LPS, fixed, and added to wells containing L-929 cells
together with (0) or without (•) anti-mouse TNFa antiserum. Mesan-
gial cells which had not been preincubated with LPS (A) were also
studied as control. Means and SEM of values obtained in 3 experiments
are given.
field and epipolarization microscopy (Leitz-Orthoplan, Wet-
ziar, Germany).
Analysis by cell sorter (FACS)
Unactivated or LPS-activated mesangial cells were fixed as
indicated above and resuspended in PBS before addition of 20
d per ml anti-mouse TNFs antiserum or normal rabbit serum
as control. Incubations were performed at room temperature
for 30 minutes. After washing, labeling of this primary antibody
was carried out in a second 30-minute incubation period with 50
d per ml of a fluorescein-linked donkey anti-rabbit Ig antibody
(Amersham). After washing, fluorescence analysis was per-
formed on a Ortho Cytofluorograph 50 L at a rate of about 200
cells/sec. The gate window was determined by the forward light
scatter and right angle light scatter. For each determination,
5,000 to 10,000 cells were analyzed. The green fluorescence was
detected in linear mode through a narrow band-pass filter at 514
to 545 nm. All data were collected in list mode and analyzed
with a DS1 computer (Ortho Diagnostic Systems). The results
are expressed as the percentage of fluorescence positive cells
and the mean fluorescence intensity.
Metabolic labeling of mesangial cells and
immunoprecipitation
Confluent monolayers of mesangial cells were incubated for
150 minutes at 37°C in 1 ml RPMI-1640 medium lacking cysteine
and methionine (Institut Jacques Boy, Compiegne, France)
supplemented with 10 jd FCS, 1 g LPS, 250 Ci 35S cysteine
(>600 Ci/mmol, Amersham), and 250 j,Ci 35S methionine
(>1000 Cilmmol, Amersham). The conditioned medium was
removed, and the cells were solubilized on ice in 0.2 ml
immunoprecipitation buffer (20 mrvi Tris-HCI, pH 8.0, 150 mr't
NaCI, 1% Nonidet P-40, 5 m EDTA, 1 mri PMSF). Debris
were removed from the conditioned medium by centrifugation
and 5 x immunoprecipitation buffer was added to yield 1 x final
concentration. Both cell lysate and conditioned medium were
then processed identically. Each sample (0.2 ml) was pre-
cleared by incubation for 90 minutes at 4°C with 20 d of
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protein-A Sepharose (C1-4B Pharmacia, Uppsala, Sweden) in
PBS. The supernatant was recovered by centrifugation and
either 5 pA anti-mouse TNFa antiserum (Genzyme) or 5 pA
preimmune serum were added and incubated overnight. Im-
mune complexes were adsorbed to protein-A Sepharose for 60
minutes at 4°C. The beads were washed five times with 50 mM
Tris-HC1, pH 7.5, 150 m NaCI, 0.05% Nonidet P-40, 5 mM
EDTA, 0.02% NaN3, 0.25% gelatin. The proteins were released
from the beads by boiling in sample buffer (50 mM Tris-HC1, pH
6.8, 1% SDS, 10% glycerol, and bromophenol blue), and
separated on 12.5% SDS polyacrylamide gels. The gels were
dried and developed by autoradiography.
Statistical analysis
Results are given as the mean standard error of the mean
(sEM). The statistical significance of differences between groups
was analyzed by the Student's I-test for unpaired samples.
Analysis of covariance was used to compare the slopes of two
regression lines. A P value < 0.05 was considered significant.
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Fig. 3. Cytotoxic activity of plasma membranes isolated from mesan-
gial cells exposed for two hours to I g/ml LPS. Means of values
obtained in 2 experiments are given.
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Fig. 4. Demonstration of membrane-associated TNF in mesangial cells by light microscopy using the IGSS technique. Mesangial cells were
preincubated for two hours with (3,4) or without (1,2) 1 gIml LPS, fixed, and treated with anti-mouse TNFu antiserum followed by
biotin-streptavidin-gold staining and silver amplification. Photographs were taken with combined bright-field and epipolarization microscopy (1,3),
or with epipolarization microscopy alone (2,4) at x 800 magnification.
Results
Induction and kinetics of cell surface expression and release
of TNF by LPS-stimulated mesangial cells
Both supernates of LPS-activated mesangial cells and fixed
LPS-activated mesangial cells themselves were capable of
promoting the lysis of the TNF-sensitive target cells L-929 as
evidenced in the 51Cr-release assay (Fig. 1). Cell associated
TNF activity was demonstrable after less than one hour expo-
sure to LPS, peaked at two hours and decreased progressively
thereafter while TNF activity increased in the supernate. The
percent of cytotoxicity depended on the number of fixed
LPS-activated mesangial cells added in the assay (Fig. 2), but
not on the time of paraformaldehyde fixation. In contrast, fixed
untreated mesangial cells exhibited a very weak cytotoxic
activity. To determine whether the lysis of the L-929 cells was
due to TNF, further experiments were performed in which fixed
LPS-activated mesangial cells were preincubated in the pres-
ence of anti-mouse TNFa antiserum before testing in the
cytotoxicity assay. Figure 2 shows that the cytotoxic activity of
LPS-activated mesangial cells could be almost completely
neutralized by the anti-TNFt serum, whereas it was not mod-
ified in the presence of normal rabbit serum (data not shown).
To investigate whether cell-associated TNF corresponded to
integral proteins or to molecules attached to cell surface recep-
tors, fixed LPS-activated mesangial cells were also treated with
low pH glycine buffer. Such a treatment only tended to reduce
their cytotoxic activity against L-929 cells from 33.3 6.8% to
23.1 4.9% without reaching the level of significance. To
further rule out the possibility that the leakage of TNF from an
intracellular source accounts for the cytotoxicity of fixed
mesangial cells, plasma membranes were purified from mesan-
gial cells which had been activated with LPS for two hours.
Different concentrations of plasma membranes were added to
wells containing 51Cr-labeled L-929 cells. As shown in Figure 3,
they produced cytolysis in a dose-dependent manner. This
indicates that the TNF activity was in fact associated with the
membrane or other particulate structures in fixed LPS-activated
mesangial cells.
The presence of membrane-associated TNF in LPS activated
mesangial cells has been confirmed by immunohistochemical
demonstration. Examination by the IGSS technique of unstim-
ulated mesangial cells revealed no TNF-labeled cells (Fig. 4: 1
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Fig. 6. Immunoprecipitation of TNF from mesangial cells. Cells were
incubated with 35S cysteine and 35S methionine together with 1 sg/ml
LPS, Cell-conditioned medium and cell lysate were subjected to immu-
noprecipitation with normal rabbit serum (lanes 2 and 4) or with rabbit
anti-mouse TNFa antiserum (lanes 1 and 3), and the precipitates were
run on 12.5% SDS polyacrylamide gels. Autoradiograms of these gels
are shown.
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Fig. 5. Flow cytometry analysis of membrane-associated TNFa in
mesangial cells. Mesangial cells were preincubated for two hours with
1 g/ml LPS, and fixed. Analysis is shown after labeling of cells with
normal rabbit serum and fluorescein-linked anti-Ig antibody (A), or with
anti-mouse TNFa antiserum and fluorescein linked anti-Ig antibody
before (B) and after (C) pretreatment with low pH glycine buffer.
Results are from one representative experiment out of a series of 3 to 7
experiments.
and 2). After two hours of incubation with LPS 1 LgIml, a high
proportion of mesangial cells showed a staining on their surface
which was stronger in the cell body than in the cell processes
(Fig. 4: 3 and 4). There was no staining of extracellular matrix.
To determine the percentage of mesangial cells expressing
cell surface-associated TNF molecules, the flow cytometry
assay of the response of individual cells to LPS (1 /Lg/ml for 2
hr) was performed. The expression of TNF was detected by
comparing histograms obtained with negative controls (cells
labeled by normal rabbit serum followed by fluorescein-linked
anti-Ig antibody; Fig. 5A) with those of cells labeled by anti-
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Fig. 7. Effect of increasing concentrations of DFX (•) and DMTU(O)
on TNF secretion by mesangial cells. Incubations of mesangial cells
were carried out for 18 hours with 1 zg/ml LPS. Means of values
obtained in 2 to 3 experiments are given.
TNFa antiserum followed by fluorescein linked anti-Ig antibody
(Fig. 5B). Less than 5% of control cells were positive with a
mean fluorescence intensity of 9.5 2.9 (N = 3), whereas the
percentage of LPS-activated cells stained with anti-TNFc anti-
serum was 66.2 8.6% (N 7), with a mean fluorescence
intensity of 94.6 8. These results suggest that about two-
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Fig. 8. Time course of the effect of DFX on TNF secretion by mesan-
gialcells. Incubations were carried out with I sg/ml LPS together with(0) or without (•) 5 msi DFX. Means and SEM ofvalues obtained in 3
(1 hr, 8 hr, 10 hr), 5 (12 hr), and 6 (2 hr, 4 hr, 6 hr, 18 hr) experiments
are given. Asterisks denote values significantly different from control
values at 0.05 <P < 0.005(*)orP <0.005 (**). Inset: time-dependency
of the decay of TNF activity released into the medium of LPS-activated
mesangial cells, in the absence (•) or presence (LI) of 5 mrvi DFX.
thirds of mesangial cells express TNF at their surface upon two
hours of LPS stimulation. A partial reduction of this expression
was observed after treatment with low pH glycine buffer since
the total percentage of cells stained with ariti-TNFcs antiserum
fell from 67.4 to 39.2% with a mean fluorescence intensity
decreasing from 83.7 to 73.4 (Fig. 5C).
The presence of membrane-associated TNFa was finally
assessed by immunoblotting. Mesangial cells were labeled with
35S cysteine and 35S methionine and were treated with LPS.
Immunoprecipitation with rabbit anti-mouse TNFa antiserum
showed a 17 kDa band in the cell-conditioned medium and a 26
kDa band in the cell lysate. These bands were not detectable
when preimmune serum was used (Fig 6).
Effect of desferrioxamine on cell surface expression and
secretion of TNF by LPS-activated mesangial cells
The ability of DFX to dose-dependently affect TNF secretion
by LPS-activated mesangial cells was first evaluated. At the
concentrations used in these experiments, DFX was not toxic
for mesangial cells as determined by 51Cr and LDH-release
assays: after addition of 5 mM DFX for 18 hours, the sponta-
neous releases of 51Cr and LDH were multiplied by 0.91 and
0.93, respectively (N 2). Moreover, increasing DFX concen-
trations up to 10 m only minimally affected the TNF activity
measured in the L-929 bioassay. Nevertheless, to exclude the
possibility that the decrease of TNF activity was not due to a
reduction of TNF concentration but instead was the conse-
quence of the presence of DFX in the medium, TNF bioassays
were performed after adding comparable amounts of DFX to
each well of L-929 cells. Figure 7 shows that under these
conditions DFX dose-dependently decreased TNF secretion by
mesangial cells at 18 hours following LPS challenge. To delin-
eate a potential role for the decrease of 0H generation in the
effect of DFX, the ability of the 0H scavenger DMTU to
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Fig. 9. Flow cytometry analysis of the effect of DFX on membrane-
associated TNF in mesangial cells. Incubations were carried out for
two hours with I sg/m1 LPS together with or without 5 mM DFX.
Analysis is shown after labeling of cells with anti-mouse TNFa antise-
rum and fluorescein-linked anti-Ig antibody. Results are from one
representative experiment out of a series of 3 experiments.
reduce TNF secretion by LPS-activated mesangial cells was
also examined. As shown in Figure 7, the addition of DMTU
resulted in a marked, albeit weaker, reduction of TNF secre-
tion. Next, the time courses of TNF secretion induced by LPS
alone or together with 5 m DFX were studied. When mesan-
gial cells were incubated with DFX together with LPS, there
was first a delayed release of TNF, and then an acceleration of
its decay. After two hours of incubation with LPS, the release
of TNF activity into the medium was reduced by DFX from
51.7 5.7 to 33.7 1.9% of cytotoxicity (P = 0.Ol;N= 6; Fig.
8), whereas, on the contrary, the expression of TNF activity at
the surface of fixed cells increased significantly from 40.5 1.0
to 52.3 3.4% of cytotoxicity (P = 0.01; N 5). This
observation was confirmed by FACS analysis. Two hours after
LPS addition, the total percentage of LPS-activated cells
stained with anti-TNFa antiserum was not significantly modi-
fied by DFX (65.7 17.0% without DFX vs. 70.8 8.4% with
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DFX), but the mean fluorescence intensity increased from 76.7
1.1 to 89.1 2.2 (P = 0.009; N = 3; Fig. 9). When measured
in the supernate of LPS-activated mesangial cells after four
hours, TNF bioactivity appeared not significantly modified by
DFX. Thereafter, the decay of TNF bioactivity in the medium
was faster in the presence of DFX than under control conditions
(14.9 and 6.6% per hour, respectively; P < 0.01; Fig. 8 inset), so
that after 18 hours of incubation with LPS, TNF activity in the
medium was reduced by DFX from 35.3 6.9 to 9.0 1.9% (P
= 0.005; N = 6). At that time, no effect of DFX on the cell
surface expression of TNF was observed; the percentage of
cells stained by anti-TNFa antiserum was 32.0 and 33.4%, with
a mean fluorescence of 63.1 and 58.4 in the absence and the
presence of DFX, respectively (N = 2).
Discussion
The results presented here demonstrate that, following LPS
challenge, TNF is both released by cultured rat mesangial cells
and present in the cell membrane as a ce1l-asociated molecule.
Paraformaldehyde-fixed mesangial cells exhibited cytotoxic ac-
tivity on L-929 cells which is specific of TNF with a maximum
two hours after LPS addition (Figs. 1 and 2). A similar cytotoxic
activity was demonstrated in plasma membranes prepared from
LPS-activated mesangial cells. That TNF molecules were re-
sponsible for the lytic effect on L-929 cells can be affirmed on
the following grounds: First, the cytolysis was inhibited by an
anti-mouse TNFa antiserum (Fig. 2). Second, membrane-asso-
ciated TNF was demonstrated using the IGSS technique in a
high proportion of LPS-activated mesangial cells but not in
unactivated cells (Fig. 4). Finally, TNF antigen expression was
also detected at the surface of two-thirds of LPS-activated
mesangial cells with the highly sensitive flow cytometry assay
(Fig. 5). These findings rule out the possibility that TNF was
only present on a small number of contaminating macrophages.
Such an hypothesis could have been advanced since cell-
associated TNF has been demonstrated in up to 60% of LPS-
stimulated mouse peritoneal macrophages by immunohisto-
chemical analysis [211. It was proposed in this study that TNF
was present both at the cell surface and in the cytoplasm.
Because we performed the immunolocalization experiments on
cells which had not been treated by methanol and hence
maintained membrane integrity, a possible cytoplasmic expres-
sion of TNF in mesangial cells could not be demonstrated.
Membrane-associated TNF may potentially be an integral
membrane protein or a molecule attached to its receptor. In
previous studies we have characterized several biological ef-
fects of TNF which indirectly indicate the existence of TNF
receptors on cultured rat mesangial cells [221. Because a small
proportion of membrane-associated TNF could be eluted from
the plasma membranes of mesangial cells by low pH treatment
(Fig. 5), it is likely that TNF is for one part bound to these
receptors. Nevertheless, membrane-associated TNF seems to
be present predominantly as an integral protein since the
reduction of TNF activity induced under these conditions did
not exceed 30%. Direct determination of the molecular weight
of the integral protein has shown that this protein belongs to the
26 kDa species described previously on monocytes [5] and
macrophages [6]. The time lag between the expression of
membrane-associated TNF and the secretion of TNF into the
medium of mesangial cells following LPS challenge together
with the temporal association between the decay of membrane-
associated TNF activity and the rise of TNF activity in the
medium (Fig. 1) suggest that the release of 17 kDaTNF depends
for one part on the cleavage of the integral membrane 26 kDa
molecules. A role for the neutral proteinases secreted by
mesangial cells [23] under the control of interleukin I [241 in
mediating this cleavage is not unlikely.
Whether membrane-associated TNF expressed by LPS-acti-
vated mesangial cells plays any pathophysiological role in
modulating the functions of the neighboring cells is still un-
known. Because of their proximity, it could interact with the
binding sites present on mesangial and endothelial cells as well
as on inflammatory cells (monocytes/macrophages and neutro-
phils) invading the glomerulus. In mesangial cells, TNF could
induce a weak mitogenic response [25], a stimulation of the
production of prostaglandins [22, 26, 27], cyclic AMP [22], and
ROS [15], together with an increased expression of the MHC
class II antigen 1281, and of the tissue factor-like procoagulant
activity [291. In endothelial cells, TNF could induce similar
effects and cause increased cell surface expression of adhesion
molecules for leukocytes (reviewed in 30]. Finally, TNF might
also act on leukocytes in which it has been shown to promote
ROS release [31].
These observations raise the question whether ROS could in
turn affect the cell surface expression and release of TNF by
LPS-activated mesangial cells, The present study demonstrates
that DFX reduces the concentration of TNF in the medium
through a decrease of its release and an acceleration of its
inactivation. In addition, DFX slightly and transitorily in-
creases the expression of membrane-associated TNF. The fact
that both DFX and DMTU are effective to modify TNF
synthesis suggests that OH' is involved and thus must be
generated by mesangial cells. Indeed, the ability of mesangial
cells to produce both superoxide anion (Or) and hydrogen
peroxide (H202) [32], and hence 0H through the Haber-Weiss
reaction, has been well established in vitro. There are at least
two different ways in which DFX might decrease the release of
TNF from LPS-activated mesangial cells. First, DFX could
regulate TNF synthesis at the level of gene transcription as well
as at a post-transcriptional level as demonstrated with prosta-
glandin E2 [33]. Second, DFX could indirectly interfere with the
generation of TNF when its 26 kDa precursor form is processed
to yield a 17 kDa molecule. Because by two hours after LPS
addition, DFX inhibited the release of TNF into the medium
(Fig. 8), but enhanced its cell surface expression (Fig. 9), it is
tempting to speculate that this drug prevents the mechanism of
TNF detaching from the membrane. This hypothesis is consis-
tent with that offered earlier [16] for the ability of OH or of its
metabolites to induce the cleavage of membrane-associated
TNF. This event could depend on the activation of latent
metalloproteinases [34] and/or the inactivation of proteinase
inhibitors.
Our results indicate that the mechanisms whereby DFX
reduces TNF concentration in the medium of LPS-activated
mesangial cells also involve an acceleration of its decay (Fig. 8).
Inactivation of the TNF molecule could result from the activity
of proteolytic enzymes [351, either in the medium or in endo-
somes after internalization of the ligand-receptor complex. It
could also depend on the interaction between TNF and a TNF
inhibitor [36]. In this context, it is possible that DFX prevents
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the degradation of a TNF inhibitor by blocking its oxidative
damage in the presence of 0H or 0H metabolites. The ability
of cultured mesangial cells to release such a TNF inhibitor has
never been demonstrated. It could result, as demonstrated in
human serum [36], from the proteolytic processing of the TNF
receptor molecule.
Whatever the mechanisms of its inhibitory effects, adminis-
tration of DFX during the septic shock might decrease the
release of TNF from the glomerular cells into the blood stream
and hence its systemic toxicity, while maintaining its local
effects.
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